Literature DB >> 12867117

Non-Hodgkin lymphoma.

Linda S Evans1, Barry W Hancock.   

Abstract

Non-Hodgkin lymphoma is a non-specific term that includes several lymphoproliferative malignant diseases with different clinical and histological appearances. Here, we concentrate on adult lymphomas. We look at their molecular basis, at the development of a classification system based on a better understanding of the biology of the various subgroups, and at how refinement of adverse prognostic factor groupings helps in clinical management. Lymphomas can present in various ways and be difficult to diagnose. About a quarter of cases arise extranodally and might present special problems. Developments in cytotoxic chemotherapy have led to good long-term survival prospects for aggressive lymphoma; introduction of novel approaches, including monoclonal antibody therapy, offers promise for indolent lymphoma, and should further improve prognosis for aggressive tumours.

Entities:  

Mesh:

Year:  2003        PMID: 12867117     DOI: 10.1016/S0140-6736(03)13868-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

1.  Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma.

Authors:  Lale Kostakoglu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

2.  Acute abdomen and severe lactic acidosis can lead to a surprising diagnosis.

Authors:  Boris Jung; Lana Zoric; Gerald Chanques; Amadou Konate; David Nocca; Samir Jaber
Journal:  Intensive Care Med       Date:  2009-09-15       Impact factor: 17.440

3.  Spontaneous remission in localized diffuse large B-cell lymphoma.

Authors:  László Tamás; Eszter Sári; Gábor Répássy; Péter Szabó; Eniko Bagdi; László Krenács; Judit Demeter
Journal:  Pathol Oncol Res       Date:  2011-06-10       Impact factor: 3.201

Review 4.  Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.

Authors:  Tam Nm Dinh; Alexandra S Onea; Ali R Jazirehi
Journal:  Am J Clin Exp Immunol       Date:  2017-05-15

5.  Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma.

Authors:  K E Smedby; M Akerman; H Hildebrand; B Glimelius; A Ekbom; J Askling
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

6.  Small follicular lymphoma arising near the ampulla of vater: a distinct subtype of duodenal lymphoma?

Authors:  Takahiro Zenda; Takaharu Masunaga; Bungo Fuwa; Toshihide Okada; Yasuo Ontachi; Yukio Kondo; Shinji Nakao; Hiroshi Minato
Journal:  Int J Gastrointest Cancer       Date:  2005

7.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.

Authors:  Mariano G Cardenas; Wenbo Yu; Wendy Beguelin; Matthew R Teater; Huimin Geng; Rebecca L Goldstein; Erin Oswald; Katerina Hatzi; Shao-Ning Yang; Joanna Cohen; Rita Shaknovich; Kenno Vanommeslaeghe; Huimin Cheng; Dongdong Liang; Hyo Je Cho; Joshua Abbott; Wayne Tam; Wei Du; John P Leonard; Olivier Elemento; Leandro Cerchietti; Tomasz Cierpicki; Fengtian Xue; Alexander D MacKerell; Ari M Melnick
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

8.  Determining protein biomarkers for DLBCL using FFPE tissues from HIV negative and HIV positive patients.

Authors:  Pumza Magangane; Raveendra Sookhayi; Dhirendra Govender; Richard Naidoo
Journal:  J Mol Histol       Date:  2016-10-01       Impact factor: 2.611

9.  Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

Authors:  Thomas S Lin; Kristie A Blum; Diane Beth Fischer; Sarah M Mitchell; Amy S Ruppert; Pierluigi Porcu; Eric H Kraut; Robert A Baiocchi; Mollie E Moran; Amy J Johnson; Larry J Schaaf; Michael R Grever; John C Byrd
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

10.  Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases.

Authors:  Ana V Miletic; Amy N Anzelon-Mills; David M Mills; Sidne A Omori; Irene M Pedersen; Dong-Mi Shin; Jeffrey V Ravetch; Silvia Bolland; Herbert C Morse; Robert C Rickert
Journal:  J Exp Med       Date:  2010-10-18       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.